摘要:
The present invention relates to novel oxidative processes for substrates such as olefins, alkanes, aromatics and alcohols using metallic porphyrin or salen catalytic complexes which have been specifically designed to maximize catalytic activity, thereby enhancing efficiency, selectively and speed of oxidation of these substrates. The choice of the substituents in the metallic complexes may be varied, but must be chosen to prevent specific ligand set arrangements known to be stable and therefore less catalytically efficient. Coordination complexes, particularly porphyrins and salens having nitrosyl axial ligands and electron-withdrawing peripheral substituents are preferred. Ruthenium coordination metals are the preferred metal center, with the highly reactive catalytic species found to be Ru.sup.III.
摘要:
Disclosed is a ruthenium-phosphine complex represented by formula (I):�{RuX(L)}.sub.2 (.mu.-X).sub.3 !.sup.- �R.sub.2 NH.sub.2 !.sup.+(I)wherein R is hydrogen, an alkyl group having 1 to 5 carbon atoms, a cycloalkyl group, a substituted or unsubstituted phenyl group or a substituted or unsubstituted benzyl group; X is halogen; and L is an optically active or inactive tertiary phosphine. A process for preparing the complex (I) is also disclosed, which comprises (A) reacting a ruthenium complex represented by formula: �RuX(arene)(L)!X (wherein arene is a substituted or unsubstituted phenyl group) and an ammonium salt represented by formula (III): R.sub.2 NH.HX, or (B) reacting a ruthenium complex represented by formula: �RuX.sub.2 (arene)!.sub.2, a tertiary phosphine represented by L, and an ammonium salt (III). The complex (I) useful as a catalyst for general syntheses or asymmetric syntheses can be obtained easily in good yield.
摘要:
A process for the production of ruthenium (III) acetate solution which comprises reacting ruthenium (IV) oxide with a stoichiometric amount of a hydrazine reductant in the presence of acetic acid.
摘要:
The invention relates to enantiomerically pure bisphosphines of the general formula (I) ##STR1## where R is as defined in the description, a process for their preparation and their use in metal complexes as catalysts for asymmetric reactions, in particular asymmetric hydrogenations.
摘要:
This invention relates to a process of preparing a ruthenium complex of the formula RuH.sub.2 (PR.sub.3).sub.2 L.sub.2 wherein PR.sub.3 is an organophosphorus ligand and L is H.sub.2 or PR.sub.3 ; a catalyst comprising at least one ruthenium complex having the formula RuH.sub.2 (PR.sub.3)L.sup.1.sub.3 wherein L.sup.1 is a neutral electron pair donor ligand; a process for preparing the catalyst and its use in situ in the hydrogenation of nitriles.
摘要:
The invention relates to enantiomerically pure bisphosphines of the general formula (I) ##STR1## where R is as defined in the description, a process for their preparation and their use in metal complexes as catalysts for asymmetric reactions, in particular asymmetric hydrogenations.
摘要:
The invention relates to a novel ruthenium complex having the formula Ru(.eta..sup.3 --C.sub.6 H.sub.8 --PCy.sub.2)(PCy.sub.3)Cl, wherein Cy is cyclohexyl; its use in the preparation of RuHCl(H.sub.2)(PCy.sub.3).sub.2 and RuH.sub.2 (H.sub.2).sub.2 (PCy.sub.3).sub.2 ; and the use of the complexes as catalysts in hydrogenation, imination and reductive hydrolysis processes.
摘要:
Water soluble salt or acid forms of a transition metal phthalocyanine of formula ##STR1## where M is a transition metal, X is H, alkyl, alkoxy, halide or X's together form --C.sub.4 H.sub.4 --, each R is a ligand with a solubilizing group, and Q is N or --CY-- where Y is H, alkyl, alkoxy or halide, are surprisingly active in tests indicating photodynamic properties. Novel compounds, preparative methods and pharmaceutical compositions are included.
摘要:
This invention relates to novel chiral 1,4-diol cyclic sulfates and their use as precursors in the preparation of chiral phospholane ligands, and chiral complexes useful as catalysts for carrying out enantioselective reactions.
摘要:
Novel ruthenium complexes for use as immunosuppressive agents to prevent or significantly reduce graft rejection in organ and bone marrow transplantation are described. The ruthenium complexes can also be used as an immunosuppressant drug for T-lymphocyte mediated autoimmune diseases, such as diabetes, and may be useful in alleviating psoriasis and contact dermatitis.